Xia M, Fang Y, Cao W, Liang F, Pan S, Xu X
Molecules. 2019; 24(9).
PMID: 31035631
PMC: 6539955.
DOI: 10.3390/molecules24091661.
Niraula S, Pond G, de Wit R, Eisenberger M, Tannock I, Joshua A
Can Urol Assoc J. 2013; 7(1-2):E74-81.
PMID: 23671512
PMC: 3650799.
DOI: 10.5489/cuaj.267.
Yan Y, Marasini N, Choi Y, Kim J, Woo J, Yong C
Eur J Drug Metab Pharmacokinet. 2011; 37(3):217-24.
PMID: 22201019
DOI: 10.1007/s13318-011-0078-1.
Petrova N, Chernikov I, Meschaninova M, Dovydenko I, Venyaminova A, Zenkova M
Nucleic Acids Res. 2011; 40(5):2330-44.
PMID: 22080508
PMC: 3299988.
DOI: 10.1093/nar/gkr1002.
Woo J, Lee C, Shim C, Hwang S
Pharm Res. 2003; 20(1):24-30.
PMID: 12608532
DOI: 10.1023/a:1022286422439.
Detection of the multidrug resistance marker P-glycoprotein by immunohistochemistry in malignant lung tumours.
Beer T, Rowlands D, Crocker J
Thorax. 1996; 51(5):526-9.
PMID: 8711682
PMC: 473600.
DOI: 10.1136/thx.51.5.526.
Targeting chemosensitizing doses of toremifene based on protein binding.
Wurz G, Emshoff V, DeGregorio M, Wiebe V
Cancer Chemother Pharmacol. 1993; 31(5):412-4.
PMID: 8431976
DOI: 10.1007/BF00686157.
Differential effectiveness of a range of novel drug-resistance modulators, relative to verapamil, in influencing vinblastine or teniposide cytotoxicity in human lymphoblastoid CCRF-CEM sublines expressing classic or atypical multidrug resistance.
Hill B, Hosking L
Cancer Chemother Pharmacol. 1994; 33(4):317-24.
PMID: 8281626
DOI: 10.1007/BF00685907.
Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil, cyclosporine A and SDZ PSC 833 in dependence on extracellular pH.
Zacherl J, Hamilton G, Thalhammer T, Riegler M, Cosentini E, Ellinger A
Cancer Chemother Pharmacol. 1994; 34(2):125-32.
PMID: 7910786
DOI: 10.1007/BF00685929.
Antibodies in the study of multiple drug resistance.
Heike Y, Tsuruo T
Cytotechnology. 1993; 12(1-3):91-107.
PMID: 7764460
DOI: 10.1007/BF00744659.
Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice.
Chauffert B, Pelletier H, Corda C, Solary E, Bedenne L, Caillot D
Br J Cancer. 1990; 62(3):395-7.
PMID: 2206948
PMC: 1971452.
DOI: 10.1038/bjc.1990.305.
Rationale for immunotherapy of renal cell carcinoma.
Heicappell R, Ackermann R
Urol Res. 1990; 18(6):357-72.
PMID: 2100410
DOI: 10.1007/BF00297367.
Genetic basis of multidrug resistance of tumor cells.
Kane S, Pastan I, Gottesman M
J Bioenerg Biomembr. 1990; 22(4):593-618.
PMID: 1977744
DOI: 10.1007/BF00762963.
Patterns of cross-resistance in a multidrug-resistant small-cell lung carcinoma cell line.
Cole S
Cancer Chemother Pharmacol. 1990; 26(4):250-6.
PMID: 1973363
DOI: 10.1007/BF02897225.
Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance.
Mickisch G, Merlino G, Galski H, Gottesman M, Pastan I
Proc Natl Acad Sci U S A. 1991; 88(2):547-51.
PMID: 1671173
PMC: 50848.
DOI: 10.1073/pnas.88.2.547.
Drug resistance in oncology: from concepts to applications.
Cazin J, Gosselin P, CAPPELAERE P, Robert J, Demaille A
J Cancer Res Clin Oncol. 1992; 119(2):76-86.
PMID: 1429830
DOI: 10.1007/BF01209660.
Toremifene and its metabolites enhance doxorubicin accumulation in estrogen receptor negative multidrug resistant human breast cancer cells.
Wiebe V, Koester S, Lindberg M, Emshoff V, Baker J, Wurz G
Invest New Drugs. 1992; 10(2):63-71.
PMID: 1386843
DOI: 10.1007/BF00873119.
Augmentation by bispecific F(ab')2 reactive with P-glycoprotein and CD3 of cytotoxicity of human effector cells on P-glycoprotein positive human renal cancer cells.
Heike Y, Okumura K, Tsuruo T
Jpn J Cancer Res. 1992; 83(4):366-72.
PMID: 1354668
PMC: 5918834.
DOI: 10.1111/j.1349-7006.1992.tb00116.x.
